Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00922259 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
A Phase 1 study of Influenza a, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00922259: Completed Phase 1 study of Influenza a, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00922259 is a Phase 1 study of Influenza a that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants, below the 2,752-participant average among 10 other Influenza a trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00922259, a Phase 1 study of Influenza a, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Every year the human population suffers from seasonal outbreaks of influenza resulting in both illness and death. However, the rates of illness and death from seasonal outbreaks are significantly lower than those suffered during times of influenza pandemic, such as those experienced in 1918, 1957, and 1968. The reason for this difference lies in presence of immunity within a population. With seasonal outbreaks of influenza most people have some immunity to the circulating strain and usually only those with weakened immune systems experience serious complications. Influenza pandemics, in contrast, are the result of a completely new viral subtype to which nobody possesses an immunity, leaving everyone vulnerable to the most serious of complications. It has been estimated that the next flu pandemic could cause over 200,000 deaths and over 700,000 hospitalizations in the US alone. The need for an effective viral vaccine is high. The purpose of this study is to test the safety and immunogenicity of a live influenza A strain vaccine, which would be able to combat an influenza pandemic.
Conditions Studied
Interventions
- BIOLOGICAL Influenza A H7N7 vaccine
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT00922259 record still lists
NCT00922259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,752-participant average among 10 other Influenza a trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Influenza a appearing as the primary indexed condition, and to 1 intervention - of which Influenza A H7N7 vaccine is the first listed.
NCT00922259 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00922259 about?
NCT00922259 is a clinical study titled "Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7". Every year the human population suffers from seasonal outbreaks of influenza resulting in both illness and death. However, the rates of illness and death from seasonal outbreaks are significantly lower than those suffered during times of influenza pandemic, such as those experienced in 1918, 1957, a...
What is the current status of trial NCT00922259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-07. Estimated completion is 2012-01.
What conditions does trial NCT00922259 study?
This clinical trial studies the following conditions: Influenza a.
What interventions are being tested in trial NCT00922259?
The interventions under investigation include: Influenza A H7N7 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00922259?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00922259 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00922259's enrollment target sits among peer trials
25 10th of 10 higher than 1 of 10 other Influenza a trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza a trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
COMPLETED · Phase 3
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia